Cancer Therapy with a Parvovirus Combined with an HDAC Inhibitor

Abstract

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma.

1 . Pharmaceutical composition containing (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI). 
     
     
         2 . The pharmaceutical composition of  claim 1  containing (a) a parvovirus and (b) an HDCAI as separate entities. 
     
     
         3 . The pharmaceutical composition according to  claim 1 , wherein said parvovirus is H-1 (H-1PV) or a related rodent parvovirus. 
     
     
         4 . The pharmaceutical composition according to  claim 3 , wherein said related rodent parvovirus is LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV) or Rat virus (RV). 
     
     
         5 . The pharmaceutical composition according to  claim 1 , wherein said HDACI is sodium butyrate (NaB), trichostatin A (TSA), Valproic acid (VPA) or suberoylanilide hydroxamic acid (SAHA). 
     
     
         6 . Use of a parvovirus and an HDACI as defined in  claim 1  for the preparation of (a) pharmaceutical composition(s) for the treatment of cancer. 
     
     
         7 . The use of  claim 6 , wherein (a) the parvovirus and (b) the HDACI are sequentially administered. 
     
     
         8 . The use according to  claim 7 , wherein the parvovirus (a) is administered prior to the HDACI (b). 
     
     
         9 . The use according to  claim 6 , wherein said cancer is a brain tumor, cervical carcinoma, or pancreatic carcinoma. 
     
     
         10 . The use according to  claim 9 , wherein said brain tumor is a glioma, medulloblastoma or meningioma. 
     
     
         11 . The use according to  claim 10 , wherein said glioma is a malignant human glioblastoma. 
     
     
         12 . The use according to  claim 6 , wherein said parvovirus is administered by intratumoral administration. 
     
     
         13 . The pharmaceutical composition of  claim 1  for use in a method for the treatment of cancer. 
     
     
         14 . The pharmaceutical composition according to  claim 13 , wherein said cancer is a brain tumor, cervical carcinoma, or pancreatic carcinoma.